AI-enhanced oncology MDT 2.0: from multi-modal data synergy to value-based care reconstruction - a systematic review of clinical efficacy and socioeconomic benefits - Takeaways - MDSpire

AI-enhanced oncology MDT 2.0: from multi-modal data synergy to value-based care reconstruction - a systematic review of clinical efficacy and socioeconomic benefits

  • By

  • Shuang Liu

  • Hetong Wang

  • Lijie He

  • May 25, 2026

  • 0 min

Share

  • 1

    AI-Enhanced Oncology MDT 2.0 integrates large language models to improve decision-making in oncology multidisciplinary teams.

  • 2

    AI systems achieve concordance rates of 62-76% with human tumor boards across various cancer types, particularly in guideline-driven decisions.

  • 3

    AI excels in standardizing recommendations and identifying molecular targets but struggles with complex, individualized clinical judgments.

  • 4

    The integration of AI in oncology MDTs may reduce preparation time and improve access to subspecialty expertise, though cost-effectiveness evidence is limited.

  • 5

    The review emphasizes that AI should augment rather than replace human judgment in oncology decision-making.

Original Source(s)

AI-enhanced oncology MDT 2.0: from multi-modal data synergy to value-based care reconstruction - a systematic review of clinical efficacy and socioeconomic benefits

  • by Shuang Liu, Hetong Wang, Lijie He

  • May 25, 2026

Related Content

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2